Ghada El-Hajj Fuleihan1, Rafic Baddoura2, Robert H Habib3, Georges Halaby4, Asma Arabi5, Maya Rahme5, Ravinder J Singh6, Moustapha Kassem7, Ziyad Mahfoud8, Maha Hoteit5, Rose T Daher9, Mohamed-Faisal Kassir5. 1. Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, WHO Collaborating Center for Metabolic Bone Disorders, American University of Beirut Medical Center, Beirut, Lebanon; gf01@aub.edu.lb. 2. Departments of Rheumatology and. 3. Departments of Internal Medicine and. 4. Endocrinology, Hȏtel-Dieu de France, Beirut, Lebanon; 5. Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, WHO Collaborating Center for Metabolic Bone Disorders, American University of Beirut Medical Center, Beirut, Lebanon; 6. Division of Clinical Biochemistry and Immunology, Mayo Clinic, Rochester, MN; 7. Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark; and. 8. Department of Health Policy and Research, Weill Cornell Medical College, Doha, Qatar. 9. Pathology and Laboratory Medicine and.
Abstract
BACKGROUND: It is unclear whether and at what dose vitamin D supplementation affects insulin resistance (IR). OBJECTIVE: We sought to investigate whether vitamin D at doses higher than currently recommended decreases indexes of IR in an ambulatory population of overweight elderly subjects. DESIGN: This double-blind, randomized, controlled multicenter trial enrolled 257 elderly overweight individuals aged ≥65 y with baseline 25-hydroxyvitamin D [25(OH)D] concentrations between 10 and 30 ng/mL. All subjects received 1000 mg calcium citrate/d, with vitamin D administered weekly at an equivalent dose of 600 or 3750 IU/d. The homeostasis model assessment (HOMA) of IR index at 1 y was the primary outcome. We also assessed the McAuley index. RESULTS: In total, 222 subjects (55% women) with a mean ± SD age and body mass index (BMI; in kg/m(2)) of 71 ± 4 y and 30 ± 4, respectively, completed the study. Subjects' baseline characteristics, including IR indexes, were similar across groups: 69% had prediabetes, 54% had hypertension (47% were taking antihypertensive medications), and 60% had hyperlipidemia, nearly half of whom were receiving lipid-lowering drugs. At 1 y, mean ± SD serum 25(OH)D increased from 20 ± 7 to 26 ± 7 ng/mL in the low-dose arm (P < 0.0001) and from 21 ± 8 to 36 ± 10 ng/mL in the high-dose arm (P < 0.001). Median HOMA-IR indexes did not change compared with baseline concentrations and were similar in the high- [2.2 (IQR: 1.5, 2.9)] and low-dose [2.3 (IQR: 1.6, 3.3] treatment groups. Adjusted analyses showed that HOMA-IR was predicted by the baseline HOMA index and BMI but not by vitamin D dose, baseline serum 25(OH)D, or change in 25(OH)D. CONCLUSION:Vitamin D3 at 3750 IU/d did not improve HOMA-IR compared with the Institute of Medicine Recommended Dietary Allowance of 600 IU/d in elderly overweight individuals. This trial was registered at clinicaltrials.gov as NCT01315366.
RCT Entities:
BACKGROUND: It is unclear whether and at what dose vitamin D supplementation affects insulin resistance (IR). OBJECTIVE: We sought to investigate whether vitamin D at doses higher than currently recommended decreases indexes of IR in an ambulatory population of overweight elderly subjects. DESIGN: This double-blind, randomized, controlled multicenter trial enrolled 257 elderly overweight individuals aged ≥65 y with baseline 25-hydroxyvitamin D [25(OH)D] concentrations between 10 and 30 ng/mL. All subjects received 1000 mg calcium citrate/d, with vitamin D administered weekly at an equivalent dose of 600 or 3750 IU/d. The homeostasis model assessment (HOMA) of IR index at 1 y was the primary outcome. We also assessed the McAuley index. RESULTS: In total, 222 subjects (55% women) with a mean ± SD age and body mass index (BMI; in kg/m(2)) of 71 ± 4 y and 30 ± 4, respectively, completed the study. Subjects' baseline characteristics, including IR indexes, were similar across groups: 69% had prediabetes, 54% had hypertension (47% were taking antihypertensive medications), and 60% had hyperlipidemia, nearly half of whom were receiving lipid-lowering drugs. At 1 y, mean ± SD serum 25(OH)D increased from 20 ± 7 to 26 ± 7 ng/mL in the low-dose arm (P < 0.0001) and from 21 ± 8 to 36 ± 10 ng/mL in the high-dose arm (P < 0.001). Median HOMA-IR indexes did not change compared with baseline concentrations and were similar in the high- [2.2 (IQR: 1.5, 2.9)] and low-dose [2.3 (IQR: 1.6, 3.3] treatment groups. Adjusted analyses showed that HOMA-IR was predicted by the baseline HOMA index and BMI but not by vitamin D dose, baseline serum 25(OH)D, or change in 25(OH)D. CONCLUSION:Vitamin D3 at 3750 IU/d did not improve HOMA-IR compared with the Institute of Medicine Recommended Dietary Allowance of 600 IU/d in elderly overweight individuals. This trial was registered at clinicaltrials.gov as NCT01315366.
Authors: Anastassios G Pittas; Mei Chung; Thomas Trikalinos; Joanna Mitri; Michael Brendel; Kamal Patel; Alice H Lichtenstein; Joseph Lau; Ethan M Balk Journal: Ann Intern Med Date: 2010-03-02 Impact factor: 25.391
Authors: Mirjam M Oosterwerff; Elisabeth Mw Eekhoff; Natasja M Van Schoor; A Joan P Boeke; Prabath Nanayakkara; Rosa Meijnen; Dirk L Knol; Mark Hh Kramer; Paul Lips Journal: Am J Clin Nutr Date: 2014-06-04 Impact factor: 7.045
Authors: Peter F Schnatz; Xuezhi Jiang; Sharon Vila-Wright; Aaron K Aragaki; Matthew Nudy; David M O'Sullivan; Rebecca Jackson; Erin LeBlanc; Jennifer G Robinson; James M Shikany; Catherine R Womack; Lisa W Martin; Marian L Neuhouser; Mara Z Vitolins; Yiqing Song; Stephen Kritchevsky; JoAnn E Manson Journal: Menopause Date: 2014-08 Impact factor: 2.953
Authors: Anastassios G Pittas; Bess Dawson-Hughes; Patricia R Sheehan; Clifford J Rosen; James H Ware; William C Knowler; Myrlene A Staten Journal: Diabetes Care Date: 2014-09-09 Impact factor: 19.112
Authors: M Chakhtoura; E A Akl; S El Ghandour; K Shawwa; A Arabi; Z Mahfoud; R H Habib; H Hoballah; G El Hajj Fuleihan Journal: Osteoporos Int Date: 2016-11-22 Impact factor: 4.507
Authors: Maya Rahme; Sima Lynn Sharara; Rafic Baddoura; Robert H Habib; Georges Halaby; Asma Arabi; Ravinder J Singh; Moustapha Kassem; Ziyad Mahfoud; Maha Hoteit; Rose T Daher; Darina Bassil; Karim El Ferkh; Ghada El-Hajj Fuleihan Journal: J Bone Miner Res Date: 2017-05-18 Impact factor: 6.741
Authors: Josh Muhammad; Ellen S Chan; Todd T Brown; Pablo Tebas; Grace A McComsey; Kathleen Melbourne; Royce Hardin; Amanda L Willig; Michael T Yin; Heather Ribaudo; Edgar Turner Overton Journal: Open Forum Infect Dis Date: 2017-12-11 Impact factor: 3.835